Oncology Testing
Overview
WashU Medicine’s Clinical Genomics Laboratory processes a variety of tissue specimens for the diagnosis and monitoring of many types of cancer.
Heme Malignancies
WashU Medicine’s Clinical Genomics Laboratory offers MyeloSeq®-HD, which is a targeted next generation sequencing assay for 54 genes and gene hotspots that are recurrently mutated in myeloid neoplasms, such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs). Additionally, MyeloSeq®-HD can provide important genetic information for conditions including unexplained cytopenia, clonal cytopenia of undetermined significance (CCUS), and clonal hematopoiesis of indeterminate potential (CHIP).
The assay is intended to be used for both initial diagnosis and measurable residual disease (MRD) monitoring.
For more test details, click here.
WashU Medicine’s Clinical Genomics Laboratory offers ChromoSeq®, which is a whole genome sequencing (WGS) assay intended for the comprehensive clinical genomic profiling of known or suspected hematologic neoplasms including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). ChromoSeq® differs from standard gene panels by using high coverage WGS to identify the full breath of genomic events needed to fully classify myeloid neoplasms by WHO 5th edition and ICC guidelines.
ChromoSeq® is the only comprehensive single assay available in the United States capable of unbiased detection of chromosomal structural variants, copy number alterations, single nucleotide variants (SNVs), and insertions/deletions (indels) from DNA. The assay is intended to be used at diagnosis.
ChromoSeq® is the first WGS-based assay for cancer to be covered by Medicare.
For more test details, click here.
Solid Tumor
WashU Medicine’s Clinical Genomics Laboratory offers GatewaySeq®, which is a tumor-only, high coverage, targeted next generation sequencing assay that provides a genomic assessment of solid tumors at initial diagnosis, recurrence, or metastasis. GatewaySeq® serves to identify the most common clinically significant and targetable gene mutations, copy number alterations, structural variants, as well as microsatellite instability (MSI) and tumor mutational burden (TMB).
For more test details, click here.